OliClinomel N4-550E/OliClinomel N7-1000E

OliClinomel N4-550E/OliClinomel N7-1000E Overdosage

Manufacturer:

Baxter Healthcare

Distributor:

Zuellig Pharma

Marketer:

Baxter Healthcare
Full Prescribing Info
Overdosage
In the event of inappropriate administration (overdose and/or administration rate higher than recommended), nausea, vomiting, chills, headache, hot flush, hyperhidrosis and electrolyte disturbances and signs of HYPERvolaemia or acidosis may be observed.
Excessively rapid administration of total parenteral nutrition (TPN) solutions, including OliClinomel, can result in serious or fatal consequences (see "Precautions").
HYPERglycaemia, glucosuria and a HYPERosmolar syndrome may arise if excessive glucose is administered.
Too rapid infusion or administration of an inappropriate excessive volume may cause nausea, vomiting, chills and electrolyte disturbances.
In such situations, the infusion should be discontinued immediately.
The reduced or limited ability to metabolise the lipids in OliClinomel may result in a "fat overload syndrome", the results of which are usually reversible once the infusion of lipids has been discontinued (see also "Adverse Reactions").
In some serious cases, haemodialysis, haemofiltration or haemodiafiltration may be necessary.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in